Skip to Content

Are you based in North America? If yes, switch to our North American website →

CLL Plus Screening Panel

Catalogue Numbers
LPH 087-S (5x5 tests)
LPH 087 (5x10 tests)
CLL Plus Screening Panel

A selection of haematology probes and an alpha-satellite probe for Chronic Lymphocytic Leukaemia (CLL).

Alpha Satellite 12 Plus for CLL

Trisomy of chromosome 12 is a relatively common chromosome abnormality in B- CLL, being present in around 16% of patients, when evaluated by FISH on interphase and metaphase cells1 and is now thought to have strong prognostic significance2. This product is also available in 5 (LPH 069-S) and 10 (LPH 069) test kit sizes and has been optimised for overnight hybridisation.


Deletions of 13q14 are a common event in CLL. This region is found to be heterozygously deleted in 30-60% and homozygously deleted in 10-20% of CLL patients3.

P53 (TP53) (17p13.1)

P53 (TP53) is a tumour suppressor gene that mediates the apoptosis of damaged cells. It has been found that approximately 17% of B-CLL patients have deletions of the P53 gene4. Patients exhibiting this genotype are associated with a poor prognosis5 as they harbour a proliferating population of damaged cells.

ATM (11q22.3)

The ATM gene is an important regulatory candidate in cell damage management. When it is deleted, damaged cells are neither repaired nor apoptosed and are allowed to proliferate. Screening for deletions of ATM is important to allow informed therapy choices for CLL patients, especially as deletions confer poor prognosis5.

MYB (6q23.3)

Deletions of chromosome 6q are found in B-CLL, with breakpoints being reported in bands 6q13, q15 or q21. The MYB gene is essential in haematopoietic cell p roliferation and differentiation. It is located in band 6q23.3 and is provided as a marker for 6q deletion as it is distal to reported deletion breakpoints (6q13, 6q15 and 6q21)6.

The quality of the products we have received from Cytocell have been excellent. The FISH probes they provide to us give intense, strong signals and are a pleasure to count. What has really stood out however has been the level of support and assistance provided by Cytocell’s application specialists. The team worked very closely alongside our own during the adoption of this product and spent many hours with us perfecting the technique, going above and beyond what I would expect during the transition period. Source BioScience absolutely demand high quality products and service to be able to deliver our results with confidence, and that is what we have received from Cytocell. Neil Ryan, Laboratory Operations Manager at Source BioScience


1. Döhner et al., N Engl J Med 2000;343(26):1910-1916

2. Chiorazzi. ASH Education Book; 2012: 2012(1):76-87

3. Hammarsund M et al., FEBS Letters 2004;556:75-80

4. Döhner et al., J Mol Med 1999;77:266-81

5. Foá et al., Haematol 2013; 98(5):675-685

6. Brigaudeau and Bilhou-Nabera . del(6q) abnormalities in lymphoid malignancies. Atlas Genet Cytogenet OncolHaematol. December 1998

Area of Interest*


This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.